Data I/O Corp has taken a significant step in its growth strategy by filing a registration statement to offer nearly 5 million shares of common stock. This move is poised to enhance the company's market position and reflects its commitment to innovation in the electronics manufacturing sector.
The filing, submitted on November 19, 2026, indicates that Data I/O aims to capitalize on its established position in the market for advanced programming and security deployment solutions. This sector is crucial for manufacturers of electronic devices, particularly those utilizing flash memory and microcontrollers.
Background
Data I/O Corp, incorporated in Washington in 1969, specializes in instruments for measuring and testing electricity and electronic signals (SIC 3825). The company is publicly traded on the Nasdaq under the ticker symbol DAIO. Its recent filings include a series of Form 4s and a 10-Q, indicating ongoing activity and engagement with investors.
What the Filing Says
The registration statement outlines the resale of up to 4,944,025 shares of common stock by selling stockholders. This includes 746,266 outstanding shares, 2,705,222 shares that can be issued upon conversion of certain debentures, and 1,492,537 shares from the conversion of Series C Convertible Preferred Stock. The company will not receive any proceeds from these sales, as the selling stockholders will bear all related costs.
Impact
This filing may affect various stakeholders, including current investors, potential shareholders, and competitors in the electronic manufacturing sector. By increasing the liquidity of its shares, Data I/O could attract new investors and enhance its market visibility.
What's Next
The filing does not specify what happens next, but it indicates that the company is preparing for potential sales as soon as the registration statement becomes effective.
Read Next
BirchBioMed Inc. files amended registration for Nasdaq listing
Conexeu Sciences files for resale of 7.7 million shares
TFP Group Ltd files for IPO, targeting NYSE listing
Lucidi Bruno Reports Stock Transactions in Atea Pharmaceuticals
Atea Pharmaceuticals director sells 8,750 shares of stock
Grove Collaborative director Jason Karp increases stock holdings







